Diabetes: Lilly’s Once-Weekly Insulin Shots Effective, New Data Shows

Imagine if your “daily” insulin routine became a “weekly” calendar reminderright next to trash day and the group chat you keep muting. That’s the big idea behind Eli Lilly’s investigational once-weekly basal insulin, insulin efsitora alfa (often shortened to “efsitora”). And the latest clinical-trial results suggest the idea isn’t just convenientit’s clinically legit.

Newly published and presented Phase 3 data from Lilly’s QWINT clinical trial program show that once-weekly efsitora can lower A1C about as well as widely used once-daily basal insulins in adults with type 2 diabetes. In several studies, safety outcomesespecially clinically significant low blood sugarlooked broadly comparable, with some signals of fewer hypoglycemic events in certain settings. Translation: fewer injections, similar glucose control, and a shot at making insulin feel less like a second job.

Important note: Efsitora is still under regulatory review in the U.S. This article is for general information only and isn’t medical advice. If you have diabetes, talk with your clinician before changing any treatment.

Why a Once-Weekly Insulin Is a Big Deal (Even If You Love Needles… Somehow)

Basal insulin is the long-acting “background” insulin that helps keep blood glucose steadier between meals and overnight. For many people with type 2 diabetes, basal insulin is eventually added when lifestyle changes and non-insulin medications aren’t enough to keep glucose in range. But there’s a well-known snag: daily injections can be a barrier.

Some people delay starting insulin because it feels intimidating, complicated, or like a personal “I failed” sticker (it’s not). Others start but miss doses because real life is loud: work, family, travel, stress, and the occasional “I was sure I took it… right?” moment.

Once-weekly basal insulin aims to reduce that burden. Instead of ~365 basal injections per year, you’re looking at ~52. That doesn’t eliminate glucose monitoring, healthy habits, or other medsbut it can meaningfully simplify the baseline routine.

Quick A1C Refresher: The Scoreboard Everyone Talks About

A1C (also called HbA1c) estimates average blood glucose over roughly the past 2–3 months. It’s a cornerstone for diagnosing and managing diabetes, and it’s the main outcome many insulin trials use to judge effectiveness.

In many nonpregnant adults with diabetes, an A1C goal around 7% is commonbut targets are individualized based on age, hypoglycemia risk, comorbidities, and other factors. That “individualized” part matters a lot when you’re talking about any ultra-long-acting insulin.

Meet Efsitora: The Science Behind “One Shot, One Week”

Insulin efsitora alfa is designed to act like a basal insulinbut with a pharmacologic profile extended enough to cover an entire week. One key engineering feature is that it’s a fusion protein: a modified insulin linked to an antibody fragment (Fc), which helps it stay in the body longer by engaging natural recycling pathways.

The goal is a stable, relatively “flat” insulin effect across the weekso you don’t get a big early peak followed by a late-week crash. That flatness is not just a comfort feature; it’s part of how researchers hope to manage hypoglycemia risk while still achieving strong A1C reductions.

The “New Data”: What the QWINT Trials Showed

Lilly’s Phase 3 program is called QWINT (Once-Weekly Insulin Therapy). The trials studied efsitora across different real-world-type situations: people starting basal insulin for the first time, people switching from daily basal insulin, and people using basal-bolus regimens (basal + mealtime insulin).

Here are the highlights of the most discussed studies.

QWINT-1: Starting Basal Insulin (Fixed-Dose Simplicity)

QWINT-1 evaluated adults with type 2 diabetes who were insulin-naïve (not previously using insulin). Participants received either once-weekly efsitora or once-daily insulin glargine. The trial used a novel fixed-dose titration approacha simplified set of dosing steps intended to make insulin initiation less complicated.

Bottom line: Efsitora achieved non-inferior A1C reduction versus daily glargine at 52 weeks. In widely cited results, A1C fell by about 1.31% with efsitora vs 1.27% with glargine, landing near an average A1C around the high-6% range in both groups.

Hypoglycemia rates were generally low in this insulin-initiation population. Some reports also noted fewer hypoglycemic events with efsitora than glargine in QWINT-1, whichif borne out consistentlycould be meaningful for people who worry most about lows when starting insulin.

QWINT-2: Once-Weekly vs Daily Degludec in Insulin-Naïve Type 2 Diabetes

QWINT-2 compared once-weekly efsitora with once-daily insulin degludec (another ultra-long-acting basal insulin). Results published in a major medical journal reported that efsitora was non-inferior to degludec for reducing A1C over 52 weeks in adults with type 2 diabetes who had not previously used insulin.

In company-reported summaries, efsitora lowered A1C by roughly 1.34% compared with about 1.26% with degludec, with both groups ending near an A1C around 7% (give or take). The key takeaway isn’t that one “won” by a few hundredthsit’s that weekly dosing kept up with a best-in-class daily insulin in a large trial.

QWINT-2 also included people using GLP-1 receptor agonists, which matters because in real life, many people with type 2 diabetes are already on GLP-1 therapy when insulin enters the picture.

QWINT-3: Switching From Daily Basal Insulin (The “Already on Insulin” Crowd)

QWINT-3 studied adults with type 2 diabetes who were already using daily basal insulin and needed better control. Participants received once-weekly efsitora or once-daily degludec.

Bottom line: Efsitora again met the primary endpoint for non-inferior A1C reduction at the prespecified timepoint. Publicly reported numbers frequently cite about a 0.86% A1C reduction with efsitora vs about 0.75% with degludec at 26 weeks (with both groups ending in the high-6% to low-7% range).

This is the scenario a lot of clinicians care about: the person who’s already taking insulin, is doing many things right, but still struggles with fasting glucose or overall A1C. If weekly basal insulin can maintain similar outcomes while lowering injection burden, it may reduce the “treatment fatigue tax.”

QWINT-4: Basal-Bolus Therapy (Basal + Mealtime Insulin)

QWINT-4 focused on adults with type 2 diabetes using both basal insulin and mealtime insulin (often called “basal-bolus”). That’s a more complex setting because insulin needs are higher and day-to-day variability can be intense.

Bottom line: Efsitora showed non-inferior A1C reduction compared with daily glargine when both were used alongside mealtime insulin. Reported A1C change at 26 weeks was approximately 1.07% in both groups in company summariesessentially a tie on the primary endpoint, which is exactly what non-inferiority trials are built to test.

Hypoglycemia risk is naturally higher in basal-bolus therapy, so safety details matter here. Reports indicate broadly similar rates of clinically significant or severe hypoglycemia between the weekly and daily basal approaches in this higher-intensity population.

A Note on Type 1 Diabetes: Promising, But Trickier

Some QWINT research has included type 1 diabetes (notably QWINT-5). The big theme from public reporting is that weekly basal insulin in type 1 diabetes can achieve similar A1C outcomesbut hypoglycemia management may be more challenging, especially early in treatment and during dose optimization.

That’s not a “never” for type 1. It’s a reminder that type 1 diabetes often requires faster fine-tuning of insulin, and a weekly basal insulin has a longer tail. When the insulin lasts longer, mistakes can last longer tooso safety strategy becomes everything.

So… Is Once-Weekly Basal Insulin Better, or Just Easier?

In medicine, “easier” is not a shallow benefit. Easier can be the difference between:

• starting insulin earlier instead of delaying for years while A1C slowly climbs,
• missing fewer doses because the routine fits real life,
• lower stress for people who feel overwhelmed by daily injections, and
• better long-term outcomes if improved adherence translates into sustained control.

Some trial reports and analyses also discuss improvements in “time in range” (often measured by continuous glucose monitoring), along with patient-reported outcomes like treatment satisfaction. Those quality-of-life signals are especially important because insulin isn’t just a medicationit’s a daily (or weekly) relationship.

Safety Reality Check: What Doesn’t Go Away When Dosing Goes Weekly

Weekly insulin isn’t a free pass to stop paying attention. A few safety and practical issues remain front and center:

1) Hypoglycemia Still Matters

All insulin can cause low blood sugar. With once-weekly insulin, clinicians pay close attention to how lows are managed because the insulin’s action is prolonged. If too much insulin is taken, the effects may persist longer than with a daily product. Trials used careful titration and monitoring; real-world use would need the same respect.

2) Dose Adjustments Are Slower by Design

Daily basal insulin can be adjusted relatively quickly. Weekly insulin requires a different mindset: dosing changes may take longer to show their full effect, and short-term life events (illness, reduced appetite, steroid use, schedule changes) can complicate glucose patterns.

3) Missed Doses Are Different

Missing a daily dose can cause a noticeable gap quickly; missing a weekly dose is less frequent but potentially more disruptive. The “what do I do if I forgot?” question becomes importantone that should be answered by a clinician and the product’s official prescribing information if and when approved.

4) It Won’t Replace Mealtime Insulin for People Who Need It

A weekly basal insulin addresses baseline needs. If someone requires mealtime insulin, that part of therapy doesn’t magically disappear. The real benefit is cutting down basal injectionsnot eliminating diabetes management.

Who Could Benefit Most (If Approved)?

Based on how the trials were designed and what experts discuss publicly, once-weekly basal insulin could be particularly appealing for:

• Adults with type 2 diabetes starting insulin who feel intimidated by daily injections.
• People already on basal insulin who struggle with adherence or “injection burnout.”
• Those with stable routines who value predictability (weekly schedule = easier habit formation for some).
• Patients and clinicians focused on simplifying therapy while maintaining evidence-based glucose targets.

Access, insurance coverage, pricing, and device design (pen vs autoinjector, dosing flexibility, training support) will strongly influence who actually benefits in practice.

Regulatory Status and the Race for the First Weekly Basal Insulin in the U.S.

Weekly basal insulin has become a mini space race. Novo Nordisk’s once-weekly insulin icodec (brand name Awiqli in some markets) has been approved in several countries and has been working through the U.S. regulatory process with resubmissions after prior FDA concerns. Meanwhile, Lilly’s efsitora has moved from “promising trial readouts” to a more formal regulatory phase.

Pipeline reporting and public company disclosures indicate that efsitora has been submitted for U.S. review for type 2 diabetes, with an FDA decision timeline expected later in 2026. That means the phrase “investigational” may not stick foreverbut it’s still the correct label today.

The Bottom Line

The newest data on Lilly’s once-weekly insulin efsitora supports a clear, patient-centered message: weekly basal insulin can deliver A1C reductions comparable to leading daily basal insulins in adults with type 2 diabeteswith a safety profile that, in large studies, looks broadly similar and sometimes hints at fewer lows in specific settings.

If approved, once-weekly basal insulin won’t replace lifestyle changes, glucose monitoring, or the need for individualized care. But it could remove a major friction point: the relentless daily injection cycle that can make diabetes care feel like it never clocks out.

And if you’re thinking, “Great, another thing to remember,” don’t worryweekly insulin can still be paired with the most powerful medical technology of all time: a phone alarm labeled, “Do the shot, bestie.”

Real-World Experiences: What Once-Weekly Basal Insulin Could Feel Like (Plus the Stuff People Don’t Put in Headlines)

Experience #1: The “I’m Finally Not Avoiding Insulin” Moment. Diabetes educators often describe a familiar scene: someone with type 2 diabetes has been “almost starting insulin” for months or years. They understand the benefits. They’ve heard the talk. They’ve watched their A1C inch upward anyway. But the daily injection idea feels like a cliffone more daily obligation in a life that already has plenty. A once-weekly basal option could turn that cliff into a curb. It doesn’t remove the seriousness of insulin therapy, but it can make the first step feel more doable. And in diabetes care, doable is often the difference between “someday” and “this week.”

Experience #2: The “Fewer Injections, Same Respect for the Numbers” Reality. People sometimes assume fewer shots means fewer responsibilities. In practice, most patients who do well with insulin (daily or weekly) treat it like a skill: they pay attention to fasting glucose trends, patterns around meals, sleep, stress, and activity. A once-weekly basal insulin could make the routine feel less repetitive, but it doesn’t eliminate the need to learn your body’s patterns. Many patients report that what they really want is not “less care,” but “less hassle.” Weekly basal insulin is squarely in the “less hassle” categoryespecially for people who find daily injections emotionally draining or logistically annoying.

Experience #3: The “Week-to-Week Mindset Shift.” With daily basal insulin, people often think in 24-hour blocks: “My fasting number was high; we’ll adjust the dose tonight.” Weekly insulin requires a different mental modelmore like steering a large ship than turning a bike. It’s still steerable, but you plan your adjustments carefully, and you don’t expect instant results from small dose changes. Clinicians may spend more time up front teaching what to watch and when to check in, because confidence matters when the medication is designed to last longer.

Experience #4: The “Travel Test.” Travel is where routines go to get lost. A weekly injection schedule can be a gift here: instead of packing supplies for daily basal dosing and worrying about missed nights, someone might plan one dose around a departure date. That said, travel also brings unusual meals, weird sleep, more walking (or less), and stressall of which can shift glucose. Patients who travel a lot often say their favorite diabetes tools are the ones that reduce decisions. Weekly basal insulin could reduce one decision, while still requiring awareness and monitoring.

Experience #5: The “I Still Need Support” Truth. Whether insulin is daily or weekly, the best outcomes usually show up when people aren’t doing it alone. The difference-makers tend to be: a clinician who explains titration clearly, a pharmacist or educator who helps troubleshoot, easy access to supplies, and realistic expectations. Many patients describe the emotional relief of hearing, “This is common. You’re not failing. We’re optimizing.” If weekly basal insulin becomes available, expect the same need for educationjust with fewer injections to practice.

Experience #6: The “Hope With a Side of Caution.” The excitement around weekly insulin is real, and it’s earned. But people also want honesty: ultra-long-acting insulin changes the timeline of both benefits and mistakes. Patients often say they feel safest when their care team is upfront about hypoglycemia risk, what patterns to watch for, and how follow-up will work. In other words: fewer shots can make life easier, but good diabetes care still runs on good communication.